Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Jan 14;14(1):477-496.
doi: 10.18632/aging.203826. Epub 2022 Jan 14.

Gut microbiota in patients with Alzheimer's disease spectrum: a systematic review and meta-analysis

Chun-Che Hung  1   2 , Chiung-Chih Chang  3 , Chi-Wei Huang  3 , Rui Nouchi  4   5 , Chia-Hsiung Cheng  1   2   6   7
Affiliations
Meta-Analysis

Gut microbiota in patients with Alzheimer's disease spectrum: a systematic review and meta-analysis

Chun-Che Hung et al. Aging (Albany NY). .

Abstract

Context: Gut dysbiosis has been proposed as one of pathologies in patients with Alzheimer's disease (AD) spectrum. Despite such enthusiasm, the relevant results remain substantially controversial.

Objective: A systematic review and meta-analysis were performed to investigate the differences of gut microbiota (GM) between patients with AD spectrum (including mild cognitive impairment [MCI] and AD) and healthy controls (HC).

Data sources: PubMed, MEDLINE, Scopus, and Cochrane Library from January 2000 to August 2021. Eligibility criteria for study selection: Observational trials and pre-intervention data of intervention trials that investigated the abundance of GM in patients with AD spectrum and HC.

Data extraction and synthesis: Two reviewers independently identified articles, extracted data, and evaluated the risk of bias. The effect sizes were performed by a random-effect, inverse-variance weighted model. The effects of different countries and of clinical stages on GM abundance were also examined.

Results: 11 studies consisting of 378 HC and 427 patients with AD spectrum were included in the meta-analysis. Patients with AD, but not MCI, showed significantly reduced GM diversity as compared to HC. We also found more abundance of Proteobacteria, Bifidobacterium and Phascolarctobacterium, but less abundance of Firmicutes, Clostridiaceae, Lachnospiraceae and Rikenellaceae in patients with AD spectrum as compared with HC. The profiles of abundance of Alistipes and Bacteroides in HC and AD spectrum were differentially affected by countries. Finally, when considering clinical stage as a moderator, the comparisons of abundance in Clostridiaceae and Phascolarctobacterium showed large effect sizes, with gradient changes from MCI to AD stage.

Limitations: The inclusion of studies originating only from China and the U.S. was a possible limitation.

Conclusions: Patients with AD spectrum demonstrated altered GM abundance, which was differentially mediated by countries and clinical stages.

Keywords: Alzheimer’s disease; dysbiosis; gut microbiota; meta-analysis; mild cognitive impairment; systematic review.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: The authors declare no conflicts of interest related to this study.

Figures

Figure 1
Figure 1
Flow diagram of selected studies.
Figure 2
Figure 2
Forest plots of Shannon index (A) and Simpson index (B) in the comparisons between healthy controls (HC) and Alzheimer’s disease (AD) spectrum. Patients with AD spectrum consisted of mild cognitive impairments (MCI) and AD.
Figure 3
Figure 3
Forest plots of alterations of gut microbiota in the phylum level, including Actinobacteria (A), Bacteroidetes (B), Firmicutes (C), and Proteobacteria (D). Abbreviations: AD: Alzheimer’s disease; MCI: mild cognitive impairments; CI: cognitive impairments.
Figure 4
Figure 4
Forest plots of alterations of gut microbiota in the class level, including Bacteroidia (A), Clostridia (B), and Gammaproteobacteria (C). Abbreviations: AD: Alzheimer’s disease; MCI: mild cognitive impairments; CI: cognitive impairments.
Figure 5
Figure 5
Forest plots of alterations of gut microbiota in the order level, including Bacteroidales (A), Clostridiales (B), and Enterobacteriale (C). Abbreviations: AD: Alzheimer’s disease; MCI: mild cognitive impairments; CI: cognitive impairments.
Figure 6
Figure 6
Forest plots of alterations of gut microbiota in the family level, including Bacteroidaceae (A), Clostridiaceae (B), Enterobacteriaceae (C), Lachnospiraceae (D), Rikenellaceae (E), and Ruminococcaceae (F). Abbreviations: AD: Alzheimer’s disease; MCI: mild cognitive impairments; CI: cognitive impairments.
Figure 7
Figure 7
Forest plots of alterations of gut microbiota in the genus level, including Alistipes (A), Bacteroides (B), Bifidobacterium (C), Blautia (D), and Phascolarctobacterium (E). Abbreviations: AD: Alzheimer's disease; MCI: mild cognitive impairments.
See this image and copyright information in PMC

References

    1. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, et al., and Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on “The Preclinical State of AD”; July 23, 2015; Washington DC, USA. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016; 12:292–323. 10.1016/j.jalz.2016.02.002 - DOI - PMC - PubMed
    1. Zhang ZH, Wu QY, Zheng R, Chen C, Chen Y, Liu Q, Hoffmann PR, Ni JZ, Song GL. Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model. J Neurosci. 2017; 37:2449–62. 10.1523/JNEUROSCI.3229-16.2017 - DOI - PMC - PubMed
    1. Bonfili L, Cecarini V, Cuccioloni M, Angeletti M, Berardi S, Scarpona S, Rossi G, Eleuteri AM. SLAB51 Probiotic Formulation Activates SIRT1 Pathway Promoting Antioxidant and Neuroprotective Effects in an AD Mouse Model. Mol Neurobiol. 2018; 55:7987–8000. 10.1007/s12035-018-0973-4 - DOI - PMC - PubMed
    1. Kim MS, Kim Y, Choi H, Kim W, Park S, Lee D, Kim DK, Kim HJ, Choi H, Hyun DW, Lee JY, Choi EY, Lee DS, et al.. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer's disease animal model. Gut. 2020; 69:283–94. 10.1136/gutjnl-2018-317431 - DOI - PubMed
    1. Zhang L, Wang Y, Xiayu X, Shi C, Chen W, Song N, Fu X, Zhou R, Xu YF, Huang L, Zhu H, Han Y, Qin C. Altered Gut Microbiota in a Mouse Model of Alzheimer's Disease. J Alzheimers Dis. 2017; 60:1241–57. 10.3233/JAD-170020 - DOI - PubMed

Publication types